NCT03643107Phase 2Completed

Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2021-10-01Actual

Enrollment · participants15Actual

Source updated2025-01-23Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Metastatic Castration-Resistant Prostate Cancer Patients

Treatments or interventions studied

IrofulvenDrug

Primary outcomes · main study measures

measure: Anti-tumor effect of Irofulven with prednisolone; description: Objective response rate defined as complete response, partial response or stable disease \> 9 weeks according to RECIST 1.1 for patients with measurable disease and defined as stable disease \> 9 weeks according to Prostate Cancer Working Group 3 (PCWG3) for bone metastases; timeFrame: one year

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history